---
title: treatment of small lymphocytic lymphoma
alias: rx-CLL
date: "2023-01-22"
enableToc: false
---

> [!info]
>
> 🌱 來自: [[small lymphocytic lymphoma]]

# treatment of small lymphocytic lymphoma

(NEJM 2020;383:460)

- unless “active disease”:
  [[Rai System]] III/IV, [[Binet stage]] C, disease-related sx, progressive disease, AIHA or ITP refractory to steroids, recurrent infections

## First-line

w/o del(17p)/TP53 use acalabrutinib or ibrutinib (BTK ❌inhibtors) or venetoclax + rituximab; with del(17p)/TP53 use acalabrutinib or venetoclax ± obinutuzumab; ibrutinib + venetoclax w 88% w/ CR but ↑ tox (NEJM 2019;380:2095)

## Second-line & beyond

in general, choose Rx w/ mechanism different from 1st line Rx. BTK ❌inhibtors (eg, [[zanubrutinib]]), venetoclax, chemo including fludarabine, chlorambucil, or bendamustine + rituximab. Consider allo-HSCT in relapse.

- HSCT is the only curative Rx. Rx choice balances patient/disease characteristics and goals of care. Different rates of complete remission, time to progression, and toxicities.

- Rx for complications: PCP, HSV, VZV Ppx; AIHA/ITP → steroids; recurrent infxns → IVIg

## NEW Drugs

- Bruton’s tyrosine kinase (**BTK**) ❌inhibtor
  - ibrutinib, Acalabrutinib
- BCL2 ❌inhibtor:
  - Venetoclax (**ABT-199**)
- Anti-CD20 monoclonal antibody:
  - [[obinuTUzumab]] (GA101)
- Phosphatidylinositol-3-kinase (PI3K) ❌inhibtor:
  - [[ideLAlisib]]
  - [[duVElisib]]
- Anti-CD52:
  - Alemtuzumab
